Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)

二甲双胍 医学 安慰剂 常染色体显性多囊肾病 肾功能 耐受性 多囊肾病 泌尿科 内科学 不利影响 肾脏疾病 病理 替代医学 胰岛素
作者
Ronald D. Perrone,Kaleab Z. Abebe,Terry Watnick,Andrew D. Althouse,Kenneth R. Hallows,Christina M. Lalama,Dana C. Miskulin,Stephen L. Seliger,Cheng Tao,Peter C. Harris,Kyongtae T. Bae
出处
期刊:Kidney International [Elsevier BV]
卷期号:100 (3): 684-696 被引量:47
标识
DOI:10.1016/j.kint.2021.06.013
摘要

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by growth of kidney cysts and glomerular filtration rate (GFR) decline. Metformin was found to impact cystogenesis in preclinical models of polycystic disease, is generally considered safe and may be a promising candidate for clinical investigation in ADPKD. In this phase 2 two-year trial, we randomly assigned 97 patients, 18-60 years of age, with ADPKD and estimated GFR over 50 ml/min/1.73 m2, in a 1:1 ratio to receive metformin or placebo twice daily. Primary outcomes were medication safety and tolerability. Secondary outcomes included estimated GFR decline, and total kidney volume growth. Thirty-eight metformin and 39 placebo participants still received study product at 24-months. Twenty-one participants in the metformin arm reduced drug dose due to inability to tolerate, compared with 14 in the placebo arm (not significant). Proportions of participants experiencing serious adverse events was similar between the groups. The Gastrointestinal Symptoms Rating Scale score was low at baseline and did not significantly change over time. The annual change for estimated GFR was -1.71 with metformin and -3.07 ml/min/1.73m2 per year with placebo (mean difference 1.37 {-0.70, 3.44} ml/min/1.73m2), while mean annual percent change in height-adjusted total kidney volume was 3.87% in metformin and 2.16% per year in placebo, (mean difference 1.68% {-2.11, 5.62}). Thus, metformin in adults with ADPKD was found to be safe and tolerable while slightly reducing estimated GFR decline but not to a significant degree. Hence, evaluation of efficacy requires a larger trial, with sufficient power to detect differences in endpoints.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助啥也不会采纳,获得10
刚刚
西西发布了新的文献求助10
刚刚
FLZLC发布了新的文献求助10
1秒前
OoO完成签到,获得积分10
1秒前
NexusExplorer应助小汤采纳,获得10
2秒前
华仔应助坚强百褶裙采纳,获得10
2秒前
2秒前
2秒前
2秒前
3秒前
3秒前
Flanker发布了新的文献求助10
4秒前
香菜发布了新的文献求助20
4秒前
研友_VZG7GZ应助RuiFZD采纳,获得10
5秒前
小二郎应助chen采纳,获得10
5秒前
阿阿阿啊啊a完成签到,获得积分10
6秒前
tong发布了新的文献求助10
6秒前
不舍天真完成签到,获得积分10
6秒前
师德发布了新的文献求助10
6秒前
wanli445完成签到,获得积分10
7秒前
7秒前
7秒前
桂花乌龙完成签到,获得积分10
7秒前
炙心发布了新的文献求助10
7秒前
8秒前
8秒前
9秒前
Nicolas发布了新的文献求助30
9秒前
秦无施完成签到,获得积分10
9秒前
9秒前
orixero应助西西采纳,获得10
9秒前
甜甜千兰发布了新的文献求助10
10秒前
10秒前
艾斯喜爱完成签到,获得积分10
10秒前
11秒前
晓晓发布了新的文献求助10
11秒前
TOBET发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970632
求助须知:如何正确求助?哪些是违规求助? 3515261
关于积分的说明 11177794
捐赠科研通 3250448
什么是DOI,文献DOI怎么找? 1795314
邀请新用户注册赠送积分活动 875781
科研通“疑难数据库(出版商)”最低求助积分说明 805073